Biotech News & Programmable Life

Clinical Trial Results

Regeneron reported data from its Phase 2 Pinnacle trial evaluating baloncibart, also known as REGN7544, in 82 patients with postural orthostatic tachycardia syndrome (POTS). Patients receiving a 450-mg injection experienced a mean drop in heart rate of 11.4 beats per minute compared to placebo at day eight, while a 150-mg dose reduced heart rate by 9.5 beats per minute. The high-dose group also showed sustained heart rate reductions and reported improvements in physical functioning at day 29.

Mechanism and Development

POTS is a chronic autonomic nervous system disorder associated with lightheadedness and fatigue, with no currently approved treatments. Baloncibart is an NPR1-blocking monoclonal antibody designed to increase blood volume in circulation. Regeneron plans to launch a Phase 3 study in the first half of 2027, building on this mid-stage success.

Boehringer Ingelheim presented results from the Synchronize-CVOT study at the American Heart Association Scientific Sessions, showing that survodutide achieved a hazard ratio of 0.89 in comparing major adverse cardiovascular events against placebo among 5,530 adult participants. The dual glucagon and GLP-1 receptor agonist also met secondary endpoints regarding cardiometabolic health markers.

While the drug demonstrated a meaningful weight loss of up to 13.7% at Week 72, it faces intense competition from established blockbusters like Eli Lilly's Zepbound. Furthermore, the trial noted higher discontinuation rates due to gastrointestinal adverse events, ranging between 19.3% and 20.8% across treatment arms, though company representatives express confidence that flexible dosing adjustments in future practice will mitigate this issue.

Boehringer is pursuing a dual-path regulatory strategy, aiming to seek approval for both obesity and metabolic dysfunction-associated steatohepatitis (MASH), with the initial weight loss application targeted for submission next year.

Funding and Leadership

Neurosterix announced a $105 million Series B financing led by RTW Investments, with participation from GV and Janus Henderson Investors. The company also recruited three former Karuna Therapeutics leaders, appointing Andrew Miller as executive chair, Edmund Harrigan as an independent director, and Stephen Brannan as chair of the clinical advisory board.

Drug Development Strategy

The new capital will primarily fund mid-stage trials for NTX-253, an oral muscarinic M4 positive allosteric modulator designed to treat schizophrenia. The company aims to fine-tune brain signaling to reduce psychosis symptoms while avoiding the movement and metabolic side effects typical of traditional dopamine antagonists.

Market Context

The muscarinic receptor space has gained significant attention following Bristol Myers Squibb's approval of Cobenfy and its $14 billion acquisition of Karuna. Meanwhile, other competitors like AbbVie faced setbacks when their M4 candidate emraclidine failed mid-stage trials.

IPO Details and Financials

Swiss biotech Windward Bio has filed for a Nasdaq IPO, offering 10.3 million shares priced between $16 and $18 each. According to its regulatory filing, the company expects to raise approximately $203.8 million in net proceeds, which could increase to $228 million if underwriters exercise their full options.

Core Pipeline and Chinese Assets

The primary focus of the IPO proceeds is WIN378, an anti-TSLP monoclonal antibody acquired from Kelun-Biotech and Harbour BioMed in a $970 million deal. Windward plans to use up to $227.5 million to complete ongoing phase 2 studies in chronic obstructive pulmonary disease and asthma, alongside an upcoming phase 3 trial. Additionally, the company is developing WIN027, a dual-targeting antibody licensed from Qyuns Therapeutics, with funds allocated for a phase 2b COPD study and an atopic dermatitis trial.

Investor Support and Market Context

Windward is led by CEO Luca Santarelli and has a history of strong financial backing, including a $200 million series A and a $165 million series B round. Alongside the public offering, Sanofi has agreed to purchase $50 million of Windward's stock in a private placement, underscoring major industry interest in anti-TSLP therapies for immunological and respiratory conditions.

Background

AbCellera was developing ABCL575, an antibody targeting the OX40 ligand intended to treat atopic dermatitis and other autoimmune conditions. While its phase 1 trial successfully met tolerability and pharmacokinetic goals, the company decided not to advance the candidate past this initial stage, citing external developments across the entire OX40 drug class.

Industry Context

The broader OX40 class has faced significant hurdles recently. Earlier in the year, Kyowa Kirin and Amgen halted clinical studies for rocatinlimab due to emerging malignancy concerns. Subsequently, Sanofi scrapped regulatory submission plans for amlitelimab, conceding it offered no meaningful therapeutic improvement despite originating from an expensive $1.1 billion acquisition. Conversely, some developers like Inhibrx Biosciences remain optimistic, reporting positive early results for cancer immunotherapy combinations.

Pipeline Shift

With the OX40 program shelved, AbCellera is shifting its internal focus toward other pipeline assets. Its lead candidate is now ABCL635, an NK3 receptor-targeting antibody for menopausal hot flashes, which recently achieved a phase 2 success and is positioned as a potential non-hormonal therapy competing with existing commercial options.

BioSpace reports on a turbulent period for cardiovascular drug development, highlighted by a series of late-stage clinical trial failures. According to Oppenheimer analysts, the sector experienced six clinical failures within nine weeks. Notable setbacks include Novo Nordisk's IL-6 inhibitor ziltivekimab, which failed to reduce cardiovascular risks, and Novartis's antisense therapy pelacarsen, which lowered Lp(a) levels without generating clinical benefit. Additionally, AstraZeneca and Ionis Pharmaceuticals reported a disappointing Phase 3 result for their TTR silencer Wainua.

Despite these challenges, the sector has seen positive developments. The FDA approved Eli Lilly's Mounjaro to lower cardiovascular risks in type 2 diabetes patients, and Merck secured approval for an oral PCSK9 inhibitor. Furthermore, early-stage trials showed promising results for Verve's base editor VERVE-102 in lowering LDL cholesterol.

Looking ahead, the fourth quarter brings critical readouts. NewAmsterdam Pharma anticipates Phase 3 data for its CETP inhibitor obicetrapib, while Johnson & Johnson and Bristol Myers Squibb await results from a Phase 3 trial of the oral Factor XIa inhibitor milvexian for secondary stroke prevention.